Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study
Table 4
Incidence of hypertension by cancer type and chemotherapy status.
Number of patients evaluated
Incidence of hypertension
Moderate hypertension
Severe hypertension
Crisis-level hypertension
Number of patients with moderate hypertension
Incidence rate per 100 person-years (95% CI)
Number of patients with severe hypertension
Incidence rate per 100 person-years (95% CI)
Number of patients with crisis hypertension
Incidence rate per 100 person-years (95% CI)
Overall
Total
25090
7420 (29.6%)
27.26 (18.00–39.59)
3946 (15.7%)
12.36 (6.46–21.42)
1003 (4.0%)
2.79 (0.53–8.45)
Cancer type
Breast
9049
2565 (28.3%)
18.38 (10.96–28.91)
1319 (14.6%)
8.11 (3.53–15.91)
325 (3.6%)
1.80 (0.18–6.90)
Lung
6434
1799 (28.0%)
41.42 (29.78–56.11)
913 (14.2%)
17.95 (10.63–28.38)
234 (3.6%)
4.11 (1.14–10.39)
Colorectal
4018
1446 (36.0%)
35.60 (24.88–49.38)
830 (20.7%)
16.92 (9.84–27.12)
234 (5.8%)
4.10 (1.14–10.38)
Head and neck
754
191 (25.3%)
34.82 (24.23–48.46)
102 (13.5%)
16.43 (9.47–26.51)
25 (3.3%)
3.64 (0.91–9.72)
Gastric
386
95 (24.6%)
38.83 (27.59–53.12)
52 (13.5%)
18.45 (11.02–29.00)
18 (4.7%)
5.57 (1.95–12.47)
Ovarian
763
270 (35.4%)
37.76 (26.69–51.88)
173 (22.7%)
20.24 (12.40–31.18)
49 (6.4%)
4.79 (1.51–11.37)
Cervical
313
83 (26.5%)
34.17 (23.69–47.72)
44 (14.1%)
15.73 (8.94–25.65)
9 (2.9%)
2.96 (0.60–8.70)
Renal
548
184 (33.6%)
46.72 (34.29–62.18)
86 (15.7%)
17.01 (9.91–27.23)
21 (3.8%)
3.68 (0.93–9.78)
Melanoma
751
133 (17.7%)
16.67 (9.66–26.82)
64 (8.5%)
7.26 (2.98–14.77)
18 (2.4%)
1.92 (0.22–7.10)
Prostate
1596
537 (33.6%)
38.12 (26.99–52.30)
305 (19.1%)
18.00 (10.67–28.45)
61 (3.8%)
3.06 (0.65–8.86)
Connective and other soft tissue
478
117 (24.5%)
23.02 (14.60–34.54)
58 (12.1%)
10.29 (4.99–18.76)
9 (1.9%)
1.42 (0.09–6.29)
During chemotherapy
Total
13167
3647 (27.7%)
90.07 (72.43–110.70)
1901 (14.4%)
40.21 (28.76–54.71)
478 (3.6%)
8.98 (4.10–17.06)
Cancer type
Breast
4144
1034 (25.0%)
70.45 (54.97–88.95)
508 (12.3%)
30.04 (20.28–42.88)
112 (2.7%)
5.98 (2.19–13.04)
Lung
4294
1125 (26.2%)
102.02 (83.19–123.84)
563 (13.1%)
44.27 (32.20–59.37)
142 (3.3%)
10.15 (4.90–18.58)
Colorectal
2548
908 (35.6%)
104.50 (85.43–126.56)
515 (20.2%)
48.58 (35.89–64.30)
131 (5.1%)
10.48 (5.13–19.01)
Head and neck
402
93 (23.1%)
131.01 (109.53–155.46)
46 (11.4%)
57.17 (43.32–74.04)
16 (4.0%)
18.39 (10.97–28.93)
Gastric
190
37 (19.5%)
69.48 (54.11–87.86)
21 (11.1%)
36.80 (25.88–50.77)
10 (5.3%)
16.34 (9.40–26.41)
Ovarian
588
205 (34.9%)
93.52 (75.53–114.50)
124 (21.1%)
49.42 (36.61–65.26)
37 (6.3%)
12.38 (6.47–21.44)
Cervical
169
39 (23.1%)
129.39 (108.05–153.70)
21 (12.4%)
63.82 (49.13–81.52)
3 (1.8%)
7.80 (3.32–15.50)
Renal
172
46 (26.7%)
109.22 (89.70–131.73)
21 (12.2%)
38.41 (27.24–52.63)
11 (6.4%)
19.54 (11.86–30.33)
Melanoma
100
13 (13.0%)
59.05 (44.95–76.16)
8 (8.0%)
36.54 (25.67–50.47)
3 (3.0%)
12.51 (6.57–21.61)
Prostate
381
115 (30.2%)
94.43 (76.35–115.51)
62 (16.3%)
42.12 (30.37–56.90)
10 (2.6%)
5.78 (2.07–12.76)
Connective and other soft tissue
179
32 (17.9%)
63.40 (48.76–81.06)
12 (6.7%)
20.24 (12.40–31.17)
3 (1.7%)
4.78 (1.50–11.36)
During the period with no chemotherapy
Total
22969
5057 (22.0%)
20.89 (12.92–31.97)
2621 (11.4%)
9.64 (4.55–17.92)
619 (2.7%)
2.09 (0.27–7.36)
Cancer type
Breast
8660
1973 (22.8%)
15.09 (8.46–24.85)
985 (11.4%)
6.72 (2.64–14.04)
250 (2.9%)
1.58 (0.13–6.54)
Lung
5571
971 (17.4%)
28.77 (19.23–41.38)
489 (8.8%)
13.10 (7.00–22.36)
109 (2.0%)
2.70 (0.49–8.31)
Colorectal
3576
866 (24.2%)
25.20 (16.34–37.14)
478 (13.4%)
12.35 (6.45–21.40)
133 (3.7%)
3.11 (0.67–8.93)
Head and neck
673
118 (17.5%)
24.45 (15.74–36.25)
64 (9.5%)
12.24 (6.37–21.26)
9 (1.3%)
1.58 (0.13–6.55)
Gastric
343
69 (20.1%)
33.34 (22.99–46.74)
38 (11.1%)
17.27 (10.11–27.55)
9 (2.6%)
3.54 (0.87–9.58)
Ovarian
628
158 (25.2%)
29.67 (19.97–42.43)
98 (15.6%)
16.59 (9.59–26.71)
18 (2.9%)
2.73 (0.51–8.36)
Cervical
275
53 (19.3%)
25.17 (16.31–37.10)
28 (10.2%)
11.66 (5.96–20.53)
6 (2.2%)
2.36 (0.36–7.79)
Renal
520
153 (29.4%)
43.19 (31.28–58.14)
73 (14.0%)
16.37 (9.42–26.44)
10 (1.9%)
1.98 (0.24–7.20)
Melanoma
732
124 (16.9%)
16.08 (9.20–26.08)
60 (8.2%)
7.04 (2.84–14.48)
16 (2.2%)
1.77 (0.18–6.86)
Prostate
1554
475 (30.6%)
36.43 (25.58–50.34)
260 (16.7%)
16.77 (9.73–26.93)
52 (3.3%)
2.90 (0.58–8.62)
Connective and other soft tissue
437
97 (22.2%)
21.34 (13.27–32.51)
48 (11.0%)
9.59 (4.52–17.86)
7 (1.6%)
1.26 (0.06–6.01)
Moderate hypertension: 150 mm Hg < SBP ≤ 160 mm Hg or 100 mm Hg < DBP ≤ 110 mm Hg. Severe-hypertension: 160 mm Hg < SBP ≤ 180 mm Hg or 110 mm Hg < DBP ≤ 120 mm Hg. Crisis-level hypertension: 180 mm Hg < SBP or 120 mm Hg < DBP.
